Mutational analysis of vaccinia virus mRNA cap (guanine-N7) methyltransferase reveals essential contributions of the N-terminal peptide that closes over the active site

Zheng, S.; Shuman, S.; RNA 14, 2297-2304 (2008)

 show all sequences of 2.1.1.56

Data extracted from this reference:

Engineering
Amino acid exchange Commentary Organism
D545A the mutant has 102% of wild type activity Vaccinia virus
F556A the mutant has 1% of wild type activity Vaccinia virus
F556L the mutant has 3% of wild type activity Vaccinia virus
N550A the mutant has 3% of wild type activity Vaccinia virus
N550D the mutant has 19% of wild type activity Vaccinia virus
N550Q the mutant has 10% of wild type activity Vaccinia virus
R548A the mutant has 59% of wild type activity Vaccinia virus
R560A the mutant has 18% of wild type activity Vaccinia virus
R560K the mutant has 84% of wild type activity Vaccinia virus
R560Q the mutant has 84% of wild type activity Vaccinia virus
R562A the mutant has 10% of wild type activity Vaccinia virus
R562K the mutant has 25% of wild type activity Vaccinia virus
R562Q the mutant has 23% of wild type activity Vaccinia virus
R655A the mutant has 31% of wild type activity Vaccinia virus
R794A the mutant has 124% of wild type activity Vaccinia virus
R808A the mutant has 142% of wild type activity Vaccinia virus
Y555A the mutant has 2% of wild type activity Vaccinia virus
Y555F the mutant has 94% of wild type activity Vaccinia virus
Y555L the mutant has 2% of wild type activity Vaccinia virus
Y555S the mutant has 4% of wild type activity Vaccinia virus
Organism
Organism Primary Accession No. (UniProt) Commentary Textmining
Vaccinia virus
-
-
-
Substrates and Products (Substrate)
Substrates Commentary Substrates Literature (Substrates) Organism Products Commentary (Products) Literature (Products) Organism (Products) Reversibility
S-adenosyl-L-methionine + G(5')pppR-RNA
-
 690028 Vaccinia virus S-adenosyl-L-homocysteine + m7G(5')pppR-RNA
-
-
-
 ?
Engineering (protein specific)
Amino acid exchange Commentary Organism
D545A the mutant has 102% of wild type activity Vaccinia virus
F556A the mutant has 1% of wild type activity Vaccinia virus
F556L the mutant has 3% of wild type activity Vaccinia virus
N550A the mutant has 3% of wild type activity Vaccinia virus
N550D the mutant has 19% of wild type activity Vaccinia virus
N550Q the mutant has 10% of wild type activity Vaccinia virus
R548A the mutant has 59% of wild type activity Vaccinia virus
R560A the mutant has 18% of wild type activity Vaccinia virus
R560K the mutant has 84% of wild type activity Vaccinia virus
R560Q the mutant has 84% of wild type activity Vaccinia virus
R562A the mutant has 10% of wild type activity Vaccinia virus
R562K the mutant has 25% of wild type activity Vaccinia virus
R562Q the mutant has 23% of wild type activity Vaccinia virus
R655A the mutant has 31% of wild type activity Vaccinia virus
R794A the mutant has 124% of wild type activity Vaccinia virus
R808A the mutant has 142% of wild type activity Vaccinia virus
Y555A the mutant has 2% of wild type activity Vaccinia virus
Y555F the mutant has 94% of wild type activity Vaccinia virus
Y555L the mutant has 2% of wild type activity Vaccinia virus
Y555S the mutant has 4% of wild type activity Vaccinia virus
Substrates and Products (Substrate) (protein specific)
Substrates Commentary Substrates Literature (Substrates) Organism Products Commentary (Products) Literature (Products) Organism (Products) Reversibility
S-adenosyl-L-methionine + G(5')pppR-RNA
-
 690028 Vaccinia virus S-adenosyl-L-homocysteine + m7G(5')pppR-RNA
-
-
-
 ?

See also following references to EC number 2.1.1.56 (sorted by year of publication):
No.1st authorPub
Med		titleorganimsjournalvolumepagesyearActivating CompoundApplicationCloned(Commentary)Crystallization (Commentary)EngineeringGeneral StabilityInhibitorsKM Value [mM]LocalizationMetals/IonsMolecular Weight [Da]Natural Substrates/ Products (Substrates)Organic Solvent StabilityOrganismOxidation StabilityPosttranslational ModificationPurification (Commentary)ReactionRenatured (Commentary)Source TissueSpecific Activity [micromol/min/mg]Storage StabilitySubstrates and Products (Substrate)SubunitsTemperature Optimum [°C]Temperature Range [°C]Temperature Stability [°C]Turnover Number [1/s]pH OptimumpH RangepH StabilityCofactorKi Value [mM]pI ValueIC50 ValueActivating Compound (protein specific)Application (protein specific)Cloned(Commentary) (protein specific)Cofactor (protein specific)Crystallization (Commentary) (protein specific)Engineering (protein specific)General Stability (protein specific)IC50 Value (protein specific)Inhibitors (protein specific)Ki Value [mM] (protein specific)KM Value [mM] (protein specific)Localization (protein specific)Metals/Ions (protein specific)Molecular Weight [Da] (protein specific)Natural Substrates/ Products (Substrates) (protein specific)Organic Solvent Stability (protein specific)Oxidation Stability (protein specific)Posttranslational Modification (protein specific)Purification (Commentary) (protein specific)Renatured (Commentary) (protein specific)Source Tissue (protein specific)Specific Activity [micromol/min/mg] (protein specific)Storage Stability (protein specific)Substrates and Products (Substrate) (protein specific)Subunits (protein specific)Temperature Optimum [°C] (protein specific)Temperature Range [°C] (protein specific)Temperature Stability [°C] (protein specific)Turnover Number [1/s] (protein specific)pH Optimum (protein specific)pH Range (protein specific)pH Stability (protein specific)pI Value (protein specific)ExpressionGeneral InformationGeneral Information (protein specific)Expression (protein specific)KCat/KM [mM/s]KCat/KM [mM/s] (protein specific)
704920SeliskoBiochemical characterization o ...Dengue virusJ. Gen. Virol.91112-1212010------1----1-4--------1--------------------1-----1--------1---------------
701751MilaniFlaviviral methyltransferase/R ...Dengue virus, Wesselsbron virusAntiviral Res.8328-342009------4------5--2-----2-----------2-------24---------2----2---------------
706020CowlingEnhanced mRNA cap methylation ...Homo sapiensOncogene29930-9362009-------------2-----2--1--------------------------------2--1----------11---
706535ChenFunctional screen reveals SARS ...SARS coronavirusProc. Natl. Acad. Sci. USA1063484-34892009--1-4--------5--------1--------------1--4-----------------1---------------
690028ZhengMutational analysis of vaccini ...Vaccinia virusRNA142297-23042008----20--------3--------1-----------------20-----------------1---------------
705423DongWest Nile virus methyltransfer ...West Nile virusJ. Virol.824295-43072008----20-1------1--------1-----------------20--1--------------1----------11---
706721ZhengStructure-function analysis of ...Vaccinia virusRNA14696-7052008--1-49--16-----3--1-----11---14---------1--49----16-------1----11---14----------
676231PeyraneHigh-yield production of short ...Homo sapiensNucleic Acids Res.35e262007--1----------5--1----11--------------1---------------1---11---------------
674701ZhengMutational analysis of Encepha ...Encephalitozoon cuniculi, Saccharomyces cerevisiaeJ. Biol. Chem.28135904-359132006-22145-32-----5--2-----2--1-1------2-22-145-23-2-------2----2--1-1----------
677098HallCharacterization of a Trypanos ...Trypanosoma bruceiRNA12488-4972006-11-10--------4--1-----31------------11--10------------1----31--------------
677246SchwerGenetic analysis of poxvirus m ...Vaccinia virusVirology352145-1562006-11-28--------4-----------1----------11--28--------------------1------------
659939ShaferHuman mRNA cap methyltransfera ...Homo sapiensMol. Cell. Biol.252644-26492005--1-1---2--1-3-----1--2--------------1--1-----2--1-----1--2---------------
674439HausmannEncephalitozoon cuniculi mRNA ...Encephalitozoon cuniculiJ. Biol. Chem.28020404-204122005--1138-43-----3--1----151----11-1--4--11138-44-3-------1---151----11--------
659921FabregaStructure and mechanism of mRN ...Encephalitozoon cuniculiMol. Cell1377-892004--1118------1-2--11----21-------------1-118--------1---1----21--------------
485473LiCharacterization of the Adomet ...bamboo mosaic virusJ. Virol.75782-7882001--1----------1--1-----2-1---1--------1---------------1----2-1---1---------
485470YokoskaCloning and characterization o ...Xenopus laevisBiochem. Biophys. Res. Commun.268617-6242000--1-------31-3---1-1--2--------------3----------33-----2--6---------------
485471WenCap methyltransferase selectiv ...Homo sapiensGenes Dev.142944-294920001-1---1-1----2--------1------------1-1-----1--1-----------1---------------
485466AholaSemliki forest virus mRNA capp ...Semliki forest virusEMBO J.183164-31721999--1----------4--1-----1--------------1---------------1----1---------------
485465RamadeviCapping and methylation of mRN ...bluetongue virusProc. Natl. Acad. Sci. USA9513537-135421998--1-119-2----1--11----3-1---1--------1--11-9--2------1----3-1---1---------
485469TsukamotoCloning and characterization o ...Homo sapiens, Saccharomyces cerevisiaeBiochem. Biophys. Res. Commun.25127-341998--2----------2--------2-2---2--------2--------------------2-2---2---------
485472MaoVaccinia virus mRNA (guanine-7 ...Vaccinia virusBiochemistry356900-69101996--1-6--------4---1----1-1---1--------1--6-----------------1-1---1---------
485467HigmanThe mRNA (guanine-7-)methyltra ...Vaccinia virusJ. Biol. Chem.26914974-149811994--1---15--2--1--11--1-411---1--------1-----1-5--2----1--1-411---1---------
485468MaoIntrinsic RNA (guanine-7) meth ...Vaccinia virusJ. Biol. Chem.26924472-244791994--1-1--------1--11--1-211---1--------1--1------------1--1-211---1---------
485455CongMethyltransferase and subunit ...Vaccinia virusJ. Biol. Chem.26716424-164291992--1-1-10-1-12-1---1----321-------12----1--1--1012-1-12--------321-------------
485456HigmanThe vaccinia virus mRNA (guani ...Vaccinia virusJ. Biol. Chem.26716430-164371992--1--------2-1--11----3-1---1--------1-----------2---1----3-1---1---------
485463GuoInteraction and mutual stabili ...Vaccinia virusProc. Natl. Acad. Sci. USA874023-40271990--1--1----33-1--11----4--------------1---1------33---1----4---------------
485451CrossIdentification of a unique gua ...Semliki forest virusVirology130452-4631983-----11-1--1-4-----1--3-1----------------1-1--1--1-----1--3-1-------------
485462LochtPartial purification and chara ...Saccharomyces cerevisiaeEur. J. Biochem.134117-1211983------51-41--2--1--111111---11-------------5-1-41----1-111111---11--------
485450PughEffects of S-adenosylhomocyste ...Vaccinia virusBiochemistry211535-15411982------19-1--1-1--------2-1---1--------------19--1--1--------2-1---1---------
485461Goswami2-5-Linked oligo(adenylic acid ...Mus musculus, Vaccinia virusJ. Biol. Chem.2576867-68701982------4-1----2--2--1--2-2------------------4--1------2-1--2-2-------------
485460Germershausen5 Cap methylation of homologou ...Neurospora crassaBiochem. Biophys. Res. Commun.82871-8781978-----------1-1--1--2-14-1---1--------------------1---1-2-14-1---1---------
485464MonroyPurification of mRNA guanylylt ...Vaccinia virusJ. Biol. Chem.2534481-44891978-----1--1-1--1--1----11-------2----------1----1-1----1---11-------2-------
485459PughInhibition of Newcastle diseas ...Newcastle disease virusBiochemistry163928-39321977------10-1----1--------1--------------------10--1-----------1---------------
485457EnsingerModification of the 5 terminus ...Homo sapiensJ. Biol. Chem.2515283-52911976--------231--1--1--1128-----1--1------1-------231----1-1128-----1---------
485458MartinmRNA guanylyltransferase and m ...Vaccinia virusJ. Biol. Chem.2517313-73211976--------11---1--1-----8-1---1-----------------11-----1----8-1---1---------
485452MartinPurification of mRNA guanylylt ...Vaccinia virusJ. Biol. Chem.2509322-93291975------2-1-21-1--1----1211---1---3----------23-1-21---1---1211---1---------
485453MartinModification of RNA by mRNA gu ...Vaccinia virusJ. Biol. Chem.2509330-93351975------6-11---1--------4-1------1------1----6--11----------4-1-------------
485454EnsingerModification of the 5-terminus ...Vaccinia virusProc. Natl. Acad. Sci. USA722525-25291975------2-12---1--------2-1------------------2--12----------2-1-------------